Even before that deal, AbbVie had been showing an interest in the modality, with then-CEO Richard Gonzalez telling analysts ...

Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes ...

Illumina and Regeneron are taking stakes in the health data company Truveta to help fund research that may dwarf the efforts ...

Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan ...

In an early look at its annual earnings report, Guardant Health posted revenue gains of 31%—with the $737 million total ...

Investors clearly appreciate the song that Tune Therapeutics is singing, handing over $175 million in series B funds as the ...

Telix Pharmaceuticals’ expansion phase shows no sign of running out yet, with the Australian radiopharma company paying $45 ...

As it works to build a 775-acre research campus in the Florida heat, the Moffitt Cancer Center is looking to cool things down ...

About 100 days into the CEO role at Kyverna Therapeutics, Warner Biddle has determined the strategic priorities for the ...

Blueprint Medicines is cutting funding to its clinical-stage CDK2 inhibitor even as the Ayvakit-maker pushes forward with ...

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

Bemdaneprocel will be studied in a sham-surgery controlled, double-blind trial that is expected to start in the first half of ...